Evaluation of intussusception after oral monovalent rotavirus vaccination in South Africa.
Post-licensure studies have shown an association between rotavirus vaccination and intussusception. We assessed the risk of intussusception associated with Rotarix® (RV1) administration, at six and 14 weeks of age, in an upper-middle income country, South Africa. Active prospective surveillance for intussusception was conducted in eight hospitals from September 2013-December 2017. Retrospective case enrolment was done at one hospital from July 2012-August 2013. Demographic characteristics, symptom onset and rotavirus vaccine status were ascertained. Using the self-controlled case-series method, we estimated age-adjusted incidence-rate ratios within 1-7, 8-21, and 1-21 days of rotavirus vaccination in children aged 28-275 days at onset of symptoms. In addition, age-matched controls were enrolled for a subset of cases (n=169), and a secondary analysis performed. There were 346 cases included in the case-series analysis. Post-dose one, there were zero intussusception cases within 1-7 days, and five cases within 8-21 days of vaccination. Post-dose two, 15 cases occurred within 1-7 days, and 18 cases within 8-21 days of vaccination. There was no increased risk of intussusception 1-7 days after dose one (no cases observed) or dose two (relative incidence (RI): 1·71; 95% confidence interval (CI) 0·83-3·01). Similarly, there was no increased risk 8-21 days after the first (RI: 4·01; 95% CI 0·87-10·56) or second dose (RI: 0·96; 95% CI 0·52-1·60). Results were similar for the case-control analysis. The risk of intussusception in the 21 days after the first or second dose of RV1 was not higher than the background risk among South Africa infants.